Patent ID: 11919966
Assignee: ABLYNX N.V.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 17:
18. A method for treatment of cancer, wherein said method comprises administering, to a subject in need thereof, a pharmaceutically active amount of at least one polypeptide, wherein the polypeptide comprises at least one immunoglobulin single variable domain (ISVD) that specifically binds glucocorticoid-induced TNFR family-related receptor (GITR) with an EC50 value of less than 200 pM, wherein the binding of said ISVD to said GITR enhances an immune response, and wherein the cancer is selected from squamous cell cancer, small-cell lung cancer, non-small cell lung cancer, melanoma, kidney cancer such as renal cell carcinoma and Wilms' tumors, glioblastoma, glioma, prostate cancer, testicular cancer, gastrointestinal cancer, pancreatic cancer, biliary tract cancer, cervical cancer, ovarian cancer, liver cancer, bladder cancer, breast cancer, colon cancer, colorectal cancer, small bowel or appendix cancer, uterine or endometrial cancer, multiple myeloma, salivary gland carcinoma, adrenal gland cancer, osteosarcoma, chondrosarcoma, nasopharyngeal carcinoma, basal cell carcinoma, vulval cancer, thyroid cancer, testicular cancer, esophageal cancer, head and neck cancer, leukemia, lymphomas, merkel cell cancer and other hematologic malignancies.